Clinical trial for Pharmacogenetics
Official title An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.
ClinicalTrials.gov ID: NCT07373470
What this study is testing
- What it's testing
- This study is testing whether pharmacist care using gene test results improves depression symptoms. It compares this care to usual care.
- Who it's for
- You may be able to join if you are 18 or older and need to start or change depression medicine.
- What's involved
- You would get a gene test result review from a pharmacist. You would also get your usual care from your doctor.
- Time commitment
- The study lasts until you finish your depression treatment plan.
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- New prescription or change in dose/schedule of SSRI (citalopram, escitalopram, sertraline, paroxetine), OR
- Concurrent SSRI (citalopram, escitalopram, sertraline, paroxetine) and new prescription/change in SNRI (desvenlafaxine, duloxetine, and venlafaxine)...
- Depressive symptoms confirmed by PHQ8 assessment (\>5 indicating at least mild depressive symptoms)
- UPMC patient (or able/willing to become one) and has UPMC provider (or able/willing to obtain one)
- Signed consent to join Pitt+Me Discovery biobanking research study.
You likely can't join if
- Inability to receive CMM at specific pharmacy/pharmacist
- Comorbid diagnosis of schizophrenia (patient-reported)
- Untreated sleep disorder (patient-reported)
- Pitt+Me Discovery participant who has elected to not receive return of results, or who has already received results previously
See the full eligibility criteria
- New prescription or change in dose/schedule of SSRI (citalopram, escitalopram, sertraline, paroxetine), OR
- Concurrent SSRI (citalopram, escitalopram, sertraline, paroxetine) and new prescription/change in SNRI (desvenlafaxine, duloxetine, and venlafaxine) / bupropion.
- Depressive symptoms confirmed by PHQ8 assessment (\>5 indicating at least mild depressive symptoms)
- UPMC patient (or able/willing to become one) and has UPMC provider (or able/willing to obtain one)
- Signed consent to join Pitt+Me Discovery biobanking research study.
- English-speaking
- Inability to receive CMM at specific pharmacy/pharmacist
- Comorbid diagnosis of schizophrenia (patient-reported)
- Untreated sleep disorder (patient-reported)
- Pitt+Me Discovery participant who has elected to not receive return of results, or who has already received results previously
The study team makes the final eligibility decision.
Where it is enrolling
- Pittsburgh, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Pittsburgh, Pennsylvania, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.